Leslie J Padrnos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3251794/publications.pdf

Version: 2024-02-01

1040056 888059 20 317 9 17 citations h-index g-index papers 20 20 20 679 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. Mayo Clinic Proceedings, 2020, 95, 2467-2486.	3.0	91
2	Immunotherapy in pancreatic cancer treatment: a new frontier. Therapeutic Advances in Gastroenterology, 2017, 10, 168-194.	3.2	73
3	Mayâ€Thurner syndrome and thrombosis: A systematic review of antithrombotic use after endovascular stent placement. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 70-78.	2.3	30
4	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. Thrombosis Research, 2021, 207, 150-157.	1.7	24
5	Risk of venous thromboembolism after COVIDâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 1638-1644.	3.8	24
6	Mayo Clinic Cancer Center Experience of Metastatic Extramammary Paget Disease 1998-2012. Rare Tumors, 2016, 8, 142-145.	0.6	15
7	Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. Cancer Medicine, 2020, 9, 8301-8309.	2.8	12
8	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	4.1	12
9	Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19–Positive Compared With COVID-19–Negative Patients. Mayo Clinic Proceedings, 2021, 96, 1718-1726.	3.0	11
10	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 664-672.e2.	0.4	6
11	A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 725-733.	0.8	4
12	Quality of life and disease understanding: impact of attending a patientâ€eentered cancer symposium. Cancer Medicine, 2015, 4, 800-807.	2.8	4
13	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment <scp>(COMFORT)â€I</scp> study. British Journal of Haematology, 2022, 198, 1065-1068.	2.5	4
14	Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 809-817.	4.1	2
15	Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination. Blood, 2021, 138, 4218-4218.	1.4	2
16	Complications of Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2022, 36, 353-363.	2.2	2
17	Therapeutic Plasma Exchange for Apixaban Removal in the Setting of Delayed Clearance and Life-Threatening Bleeding. Blood, 2021, 138, 4271-4271.	1.4	1
18	Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies. Blood, 2019, 134, 3387-3387.	1.4	0

#	Article	IF	CITATIONS
19	An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy. Blood, 2021, 138, 4267-4267.	1.4	O
20	Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies. Blood, 2020, 136, 16-17.	1.4	0